SANDOZ has announced a five-year partnership with Biocon Biologics which will provide it with exclusive rights to promote, sell and distribute biosimilar versions of trastuzumab and bevacizumab in Australia.
Under the agreement, Sandoz will distribute the Biocon Biologics' brands, Ogivri (trastuzumab) and Abvemy (bevacizumab), and facilitate sustained access to these medications, which were previously distributed by another pharmaceutical company to patients.
Clint Holland, General Manager, Sandoz ANZ, said, "following our spin-off from Novartis, our purpose remains unchanged to become the most valued biosimilars company".
"The Biocon Biologics partnership represents a key component of our growth strategy as an independent entity," added Holland.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Feb 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Feb 24
